Approval · Notice of Compliance 26895 · 2021
VOLTAREN: Notice of Compliance 26895
Issued October 21, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26895
- Date
- October 21, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph to reflect safety concerns during pregnancy as per Advisement Letter and serious skin reactions
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VOLTAREN | Not yet assigned | — |
| VOLTAREN SR | Not yet assigned | — |
Medicinal ingredients
- DICLOFENAC SODIUM 50 MG per TAB
- DICLOFENAC SODIUM 50 MG per SUP
- DICLOFENAC SODIUM 100 MG per SUP
- DICLOFENAC SODIUM 75 MG per TAB
- DICLOFENAC SODIUM 100 MG per TAB